ArticleViruses2023
Development of a Multi-Epitope Universal mRNA Vaccine Candidate for Monkeypox, Smallpox, and Vaccinia Viruses: Design and In Silico Analyses.
Article in Viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- mRNA lipid nanoparticle vaccines: current status, challenges and future prospects.Molecular biomedicine · 2026Review
- Toward Precision Vaccinology for Mpox: Rational Antigen Design, Next-Generation Platforms, and Immune Correlates of Protection.Tropical medicine and infectious disease · 2026Review
- Exploration of the protein and pharmacological landscape of monkeypox virus treatment: from entry point to end point.Molecular diversity · 2026Review
- mRNA vaccines against monkeypox: bridging immunoinformatics, structural vaccinology, and translational advances toward pan-orthopox immunity.Folia microbiologica · 2026Review
- Intranasal VACV VR-1354 infection impairs chemosensory function and induces olfactory bulb neuroinflammation in mice.Frontiers in immunology · 2026Article
- Immunoinformatics-based strategies for developing DNA and mRNA vaccines against monkeypox virus (MPXV).Virology journal · 2025Article
- Potential of MRNA vaccines for mpox prevention: current evidence and future directions.Annals of medicine and surgery (2012) · 2025Review
- Revolutionizing immunization: a comprehensive review of mRNA vaccine technology and applications.Virology journal · 2025Review
- Detecting Monkeypox Virus by Immunohistochemistry.Journal of cutaneous pathology · 2025Article
- Biological threat preparedness through vaccine development and stockpiling: challenges and strategic implications.Frontiers in public health · 2025Review
- Article
- Immunoreactivity Analysis of MHC-I Epitopes Derived from the Nucleocapsid Protein of SARS-CoV-2 via Computation and Vaccination.Vaccines · 2024Article
- Computational Workflow to Design Novel Vaccine Candidates and Small-Molecule Therapeutics for Schistosomiasis.Pathogens (Basel, Switzerland) · 2024Article
- Exploring computational approaches to design mRNA Vaccine against vaccinia and Mpox viruses.Immunity, inflammation and disease · 2024Article
- Dual-Target Additively Manufactured Electrochemical Sensor for the Multiplexed Detection of Protein A29 and DNA of Human Monkeypox Virus.ACS omega · 2024Article
- An overview on mRNA-based vaccines to prevent monkeypox infection.Journal of nanobiotechnology · 2024Review
- Computer-Aided Multi-Epitope Based Vaccine Design Against Monkeypox Virus Surface Protein A30L: An Immunoinformatics Approach.The protein journal · 2023Article
- Immunoinformatics and reverse vaccinology approach in designing a novel highly immunogenic multivalent peptide-based vaccine against the human monkeypox virus.Frontiers in molecular biosciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Notwithstanding the presence of a smallpox vaccine that is effective against monkeypox (mpox), developing a universal vaccine candidate against monkeypox virus (MPXV) is highly required as the mpox multi-country outbreak has increased global concern. MPXV, along with variola virus (VARV) and vaccinia virus (VACV), belongs to the Orthopoxvirus genus. Due to the genetic similarity of antigens in this study, we have designed a potentially universal mRNA vaccine based on conserved epitopes that are specific to these three viruses. In order to design a potentially universal mRNA vaccine, antigens A29, A30, A35, B6, and M1 were selected. The conserved sequences among the three viral species-MPXV, VACV, and VARV-were detected, and B and T cell epitopes containing the conserved elements were used for the design of the multi-epitope mRNA construct. Immunoinformatics analyses demonstrated the stability of the vaccine construct and optimal binding to MHC molecules. Humoral and cellular immune responses were induced by immune simulation analyses. Eventually, based on in silico analysis, the universal mRNA multi-epitope vaccine candidate designed in this study may have a potential protection against MPXV, VARV, and VACV that will contribute to the advancement of prevention strategies for unpredictable pandemics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.